Ami Claxton

4.2k total citations · 1 hit paper
28 papers, 3.2k citations indexed

About

Ami Claxton is a scholar working on Pharmacology, Dermatology and Nephrology. According to data from OpenAlex, Ami Claxton has authored 28 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pharmacology, 5 papers in Dermatology and 4 papers in Nephrology. Recurrent topics in Ami Claxton's work include Dermatology and Skin Diseases (5 papers), Allergic Rhinitis and Sensitization (4 papers) and Dialysis and Renal Disease Management (4 papers). Ami Claxton is often cited by papers focused on Dermatology and Skin Diseases (5 papers), Allergic Rhinitis and Sensitization (4 papers) and Dialysis and Renal Disease Management (4 papers). Ami Claxton collaborates with scholars based in United States, United Kingdom and Canada. Ami Claxton's co-authors include Joyce A. Cramer, RN, Howard G. Birnbaum, Maryna Marynchenko, David R. Jacobs, Carlos Iribarren, Stephen Sidney, Jean L. Forster, Patricia K. Corey‐Lisle and Colleen Wegzyn and has published in prestigious journals such as Stroke, American Journal of Public Health and The British Journal of Psychiatry.

In The Last Decade

Ami Claxton

26 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A systematic review of the associations between dose regimens and medication compliance

2001 1.9k citations Ami Claxton, Joyce A. Cramer et al. Clinical Therapeutics profile →

Peers

Countries citing papers authored by Ami Claxton

Since Specialization

Citations

This map shows the geographic impact of Ami Claxton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ami Claxton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ami Claxton more than expected).

Fields of papers citing papers by Ami Claxton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ami Claxton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ami Claxton. The network helps show where Ami Claxton may publish in the future.

Co-authorship network of co-authors of Ami Claxton

This figure shows the co-authorship network connecting the top 25 collaborators of Ami Claxton. A scholar is included among the top collaborators of Ami Claxton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ami Claxton. Ami Claxton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry 2025 ·Dermatitis ·Dawn Z. Eichenfield, Keith Knapp, Ami Claxton, Breda Muñoz, (unknown), Sanjeev Balu, (unknown), (unknown), (unknown), Jonathan I. Silverberg, Diamant Thaçi, Lawrence F. Eichenfield, Jerry Bagel, (unknown), Amy S. Paller, (unknown)	1
2	546 - Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment 2024 ·British Journal of Dermatology ·Steven R. Feldman, Annie Guérin, Marjolaine Gauthier‐Loiselle, Nisha C. Hazra, Yan Meng, (unknown), Ami Claxton, Sanjeev Balu	1
3	Respiratory syncytial virus hospitalization and mortality: Systematic review and meta‐analysis 2016 ·Pediatric Pulmonology ·Renato T. Stein, Louis Bont, Heather J. Zar, Fernando P. Polack, Caroline Park, Ami Claxton, Gerald M. Borok, (unknown), Colleen Wegzyn	235
4	End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases 2015 ·ClinicoEconomics and Outcomes Research ·Steven M. Brunelli, Christopher Blanchette, Ami Claxton, (unknown), Sandro Rossetti, Benjamín Gutiérrez	19
5	The Economic Impact of Improving Phosphate Binder Therapy Adherence and Attainment of Guideline Phosphorus Goals in Hemodialysis Patients: a Medicare Cost-Offset Model 2014 ·Advances in Therapy ·Karthik Ramakrishnan, (unknown), (unknown), Deborah P. Lubeck, Steven Wang, (unknown), Ami Claxton	11
6	Consequences of hemolytic uremic syndrome among hemodialysis patients 2014 ·Journal of Nephrology ·Steven M. Brunelli, Ami Claxton, Sunil Mehta, Emmanuel A. Anum	3
7	Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms 2013 ·International Journal of Nephrology and Renovascular Disease ·(unknown), Karthik Ramakrishnan, T. Christopher Bond, Ami Claxton, (unknown), (unknown), Scott Sibbel	82
8	Economic Implications of Treatment-Resistant Depression Among Employees 2004 ·PharmacoEconomics ·RN, Patricia K. Corey‐Lisle, Howard G. Birnbaum, Maryna Marynchenko, Ami Claxton	95
9	Attention-Deficit/Hyperactivity Disorder: Increased Costs for Patients and Their Families 2003 ·Journal of the American Academy of Child & Adolescent Psychiatry ·Andrine R. Swensen, Howard G. Birnbaum, Kristina Secnik, Maryna Marynchenko, RN, Ami Claxton	148
10	Identification of a Claims Data "Signature" and Economic Consequences for Treatment-Resistant Depression 2002 ·The Journal of Clinical Psychiatry ·Patricia K. Corey‐Lisle, Howard G. Birnbaum, RN, Maryna Marynchenko, Ami Claxton	70
11	A systematic review of the associations between dose regimens and medication compliance breakdown → 2001 ·Clinical Therapeutics ·Ami Claxton, Joyce A. Cramer, (unknown)	1877
12	PMH19: IDENTIFICATION AND ONE-YEAR COSTS OF TREATMENT-RESISTANT DEPRESSION IN A CLAIMS DATA ANALYSIS 2001 ·Value in Health ·Patricia K. Corey‐Lisle, Ami Claxton, HG Birnbaum, Maryna Marynchenko, (unknown)	1
13	Selective serotonin reuptake inhibitor treatment in the UK: Risk of relapse or recurrence of depression 2000 ·The British Journal of Psychiatry ·Ami Claxton, Zhiming Li, Jan McKendrick	59
14	Patient Compliance to a New Enteric-Coated Weekly Formulation of Fluoxetine During Continuation Treatment of Major Depressive Disorder 2000 ·The Journal of Clinical Psychiatry ·Ami Claxton, Erik de Klerk, Mark E. Parry, James M. Robinson, (unknown)	35
15	Absenteeism Among Employees Treated for Depression 1999 ·Journal of Occupational and Environmental Medicine ·Ami Claxton, Anita Chawla, Sean Kennedy	71
16	Association Between Serum Total Cholesterol and HIV Infection in a High-Risk Cohort of Young Men 1998 ·Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·Ami Claxton, David R. Jacobs, Carlos Iribarren, Seth L. Welles, Stephen Sidney, Kenneth R. Feingold	14
17	Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases 1998 ·Epidemiology and Infection ·Carlos Iribarren, David R. Jacobs, Stephen Sidney, Ami Claxton, Kenneth R. Feingold	74
18	Antidepressant prescribing patterns and risk of relapse and recurrence of depression in a primary care cohort in the United Kingdom 1998 ·European Neuropsychopharmacology ·(unknown), Ami Claxton, Jan McKendrick	1
19	Adolescent smokers' provision of tobacco to other adolescents. 1997 ·American Journal of Public Health ·Mark Wolfson, Jean L. Forster, Ami Claxton, David M. Murray	60
20	The role of social influences and tobacco availability on adolescent smokeless tobacco use 1997 ·Journal of Adolescent Health ·Raymond Boyle, Ami Claxton, Jean L. Forster	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact